Evidence Grade A — Regulatory approved. 59 published studies. 9 registered clinical trials.
Medically reviewed by a licensed medical professional
Loading...
Sulopenem (sold as Orlynvah) is an oral antibiotic — not a peptide — approved specifically for uncomplicated urinary tract infections caused by bacteria resistant to commonly used antibiotics. It represents the first new oral antibiotic class for UTIs in decades and fills an important gap: giving patients with drug-resistant UTIs a tablet they can take at home rather than requiring hospital admission for intravenous antibiotics.
Sulopenem is also known by these brand and alternate names:
59 published studies: 30 human, 5 animal, 15 in-vitro, 14 reviews
Sulopenem (Orlynvah) is approved for uncomplicated UTIs caused by ciprofloxacin-nonsusceptible bacteria. The SURE-1 trial (1,671 patients) demonstrated superiority over ciprofloxacin in the resistant population (62.6% versus 36.0% success). It did not demonstrate non-inferiority to ciprofloxacin in susceptible infections or to intravenous ertapenem in complicated UTIs.
Sulopenem is not a peptide. Its clinical significance is providing an oral treatment option for drug-resistant UTIs that would otherwise require intravenous antibiotics and hospitalisation. Its narrow approved indication reflects its specific niche in the antimicrobial resistance landscape.
Sulopenem inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins — a mechanism shared with other beta-lactam antibiotics. Its key advantage is stability against the enzymes (AmpC and extended-spectrum beta-lactamases) that many resistant bacteria use to destroy conventional oral antibiotics. This allows oral treatment of infections that previously required intravenous hospital-based antibiotics.
The SURE-1 trial showed sulopenem was clearly superior to ciprofloxacin in patients with ciprofloxacin-resistant infections (63% success versus 36%). However, it did not match ciprofloxacin for susceptible infections, and a second trial (SURE-2) failed to show it could replace intravenous antibiotics for complicated UTIs. The narrow approved indication — uncomplicated UTIs in women with limited oral alternatives — reflects these mixed results. The regulatory pathway was complex, with an initial rejection in 2021 before eventual approval in October 2024. Despite the narrow label, sulopenem fills a genuine clinical need: antibiotic-resistant UTIs are increasingly common, and avoiding hospitalisation for IV antibiotics has both patient quality-of-life and cost benefits.
PeptideTrace tracks 9 registered clinical trials for Sulopenem sourced from ClinicalTrials.gov.
Expanded Access Use of Sulopenem Etzadroxil/Probenecid for Complicated Urinary Tract Infection
Pharmacokinetics of Sulopenem Etzadroxil Plus Probenecid in Adolescents
Oral Sulopenem Versus Amoxicillin/Clavulanate for Uncomplicated Urinary Tract Infection in Adult Women
Safety, Tolerability, and Pharmacokinetics of Sulopenem in Adolescents
Sulopenem Versus Ertapenem for Complicated Intra-abdominal Infection (cIAI)
FDA ORIG 1
FDA SUPPL 1
FDA SUPPL 2
Sulopenem (brand name ORLYNVAH; administered as sulopenem etzadroxil plus probenecid tablets) is a beta-lactam antibiotic of the penem class. NOTE: This is a small molecule, NOT a peptide. Molecular weight 349.45 Da; molecular formula C12H15NO5S3. CAS number: 120788-07-0. Developed by Iterum Therapeutics. FDA approved October 25, 2024 for uncomplicated urinary tract infections caused by Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis in adult women with limited or no alternative oral treatment options. This represents the first oral penem and the first new oral UTI treatment approved in the US in over 20 years.
Sulopenem functions as a penem-class beta-lactam antibiotic that binds penicillin-binding proteins (PBPs) to inhibit bacterial cell wall synthesis. The compound demonstrates stability against AmpC beta-lactamases and extended-spectrum beta-lactamases (ESBLs), providing activity against resistant gram-negative pathogens. Oral bioavailability is achieved through the etzadroxil prodrug formulation, co-administered with probenecid which inhibits renal tubular secretion to maintain therapeutic drug levels.
SURE-1 (NCT03354598; N=1,671; uncomplicated UTI): in the ciprofloxacin-nonsusceptible population, overall success was 62.6% versus 36.0% for ciprofloxacin, demonstrating superiority (P<0.001). In the ciprofloxacin-susceptible population, non-inferiority was not met. SURE-2 (N=1,392; complicated UTI): non-inferiority to ertapenem was not demonstrated. REASSURE (NCT05584657; N=2,222): overall response 61.7% versus 55.0% for amoxicillin/clavulanate, meeting the non-inferiority primary endpoint; an ad hoc superiority analysis was also significant.
Zilucoplan is marketed as Zilbrysq (approved October 2023) for anti-acetylcholine receptor antibody-positive generalised myasthenia gravis in adults. Administered as a daily subcutaneous self-injection. In the RAISE trial, zilucoplan showed statistically significant improvements in both activities of daily living and quantitative muscle strength scores compared to placebo, with improvements evident from week one. Its key differentiator from existing complement inhibitors (eculizumab, ravulizumab) is the self-injectable format — those alternatives require hospital-based intravenous infusions. As with all complement inhibitors, patients require meningococcal vaccination before starting treatment due to increased susceptibility to meningococcal infection.
Vancomycin is marketed as Vancocin and Firvanq (approved 1958, with oral solution Firvanq approved 2018). It is the standard treatment for serious MRSA infections (bloodstream infections, endocarditis, pneumonia, bone infections) and is first-line for severe C. difficile colitis. Vancomycin requires therapeutic drug monitoring — blood levels must be checked regularly to ensure the dose is effective without causing kidney damage or hearing loss. The rise of vancomycin-resistant enterococci (VRE) and occasional vancomycin-intermediate S. aureus (VISA) strains represent ongoing challenges. Despite being nearly 70 years old, vancomycin remains irreplaceable for many serious infections, though newer alternatives like daptomycin and the lipoglycopeptides offer advantages in specific settings.
Bortezomib is marketed as Velcade (approved May 2003) for multiple myeloma and mantle cell lymphoma. Generic versions are available. Originally given intravenously, subcutaneous injection is now preferred as it causes significantly less nerve damage. The VISTA trial established bortezomib-based combination therapy as standard for newly diagnosed myeloma patients ineligible for transplant, with median time to disease progression of 24 months versus 16.6 months with older chemotherapy. Peripheral neuropathy (numbness and tingling in hands and feet) is the main dose-limiting side effect, affecting up to 30% of patients. Bortezomib transformed myeloma from a disease with a median survival of approximately 3 years to one where many patients live a decade or more with sequential treatments.
Evidence Reviews
Timelines
Deep Dives
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before making decisions about your health.
